OncoMatch/Clinical Trials/NCT05488522

SBRT With Atezo/Bev for HCC

Is NCT05488522 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SBRT + atezolizumab and bevacizumab for hepatocellular carcinoma.

Phase 1RecruitingAbramson Cancer Center at Penn MedicineNCT05488522Data as of May 2026

Treatment: SBRT + atezolizumab and bevacizumab — A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Abramson Cancer Center of the University of Pennsylvania · Philadelphia, Pennsylvania

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify